Viguerie A, Jacobson EU, Hicks KA, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes in the United States: a modeling study. Sex Transm Dis. 2024 Apr 1;51(4):299-304. doi: 10.1097/OLQ.0000000000001935
Viguerie A, Jacobson EU, Hicks KA, Bates L, Carrico J, Honeycutt A, Lyles C, Farnham PG. Assessing the impact of COVID-19 on HIV outcomes in the United States: a modeling study. Sex Transm Dis. 2024 Jan 24. doi: 10.1097/OLQ.0000000000001935
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Scalone L, Watson V, Ryan M, Kotsopoulos N, Patel R. Evaluation of patients' preferences for genital herpes treatment. Sex Transm Dis. 2011 Sep;38(9):802-7. doi: 10.1097/OLQ.0b013e318218702c
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Leone P, Fleming DT, Gilsenan A, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex Transm Dis. 2004 May 31;31(5):311-6.
Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, Afshari C, Paules RS. Assessing gene significance from cDNA microarray expression data via mixed models. J Comput Biol. 2001 Jan 1;8(6):625-37.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.